Beam Therapeutics (BEAM) PEG Ratio: History & Chart

Beam Therapeutics Inc.(BEAM)

Biotechnology · Cambridge, MA

$24.50+0.11 (+0.45%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Cambridge, MA

540 employees

www.beamtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Evans

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Beam Therapeutics Inc. (BEAM)	$2.52B	N/A	N/A	N/A	N/A
TransMedics Group, Inc. (TMDX)vs ›	$2.76B	N/A	N/A	N/A	N/A
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.16B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.74B	N/A	6.61	5.90	4.86
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.71B	N/A	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$1.00B	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$474.59M	N/A	4.41	4.41	4.41
NRC Health (NRC)vs ›	$458.62M	N/A	6.07	3.14	2.42
Shoulder Innovations, Inc. (SI)vs ›	$394.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$41.86M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Beam Therapeutics Inc. (BEAM)

$2.52B

N/A

TransMedics Group, Inc. (TMDX)vs ›

$2.76B

N/A

Recursion Pharmaceuticals, Inc. (RXRX)vs ›

$2.16B

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.74B

N/A

6.61

5.90

4.86

Intellia Therapeutics, Inc. (NTLA)vs ›

$1.71B

N/A

Teladoc Health, Inc. (TDOC)vs ›

$1.00B

N/A

NeoGenomics, Inc. (NEO)vs ›

$474.59M

N/A

4.41

NRC Health (NRC)vs ›

$458.62M

N/A

6.07

3.14

2.42

Shoulder Innovations, Inc. (SI)vs ›

$394.23M

N/A

PDS Biotechnology Corporation (PDSB)vs ›

$41.86M

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

BEAM PEG Ratio Metrics

BEAM Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics